Page results
-
This page tells you about having a Non-Tunnelled CVC Line Insertion (Vascath). This page is for those patients who have been referred to Interventional Radiology.
-
A drug commonly used to treat cystic fibrosis improved outcomes for patients with severe COVID-19 pneumonia and could be used to treat other respiratory infections, according to clinical trial results from researchers at UCLH, UCL and the Francis Crick Institute.
-
Temporary change to HIV confirmation pathway due to Bio-Rad kit supply issues
-
UCLH is pleased to present the first strategic workforce plan for University College London Hospitals NHS Foundation Trust (UCLH). Providing top quality care to all our patients is at the core of everything we do, and our diverse workforce is key to delivery.
-
This information is for patients who have been given a walking boot, including air cast boots, pneumatic walking boots and vacoped boots.
-
This information is for patients who have been given a hinge knee brace.
-
Introduction of Bordetella pertussis PCR testing at Halo laboratory (Health Services Laboratories)
-
The North Central London Integrated Care System (NCL ICS) has new services and staff training to support patients with inherited red cell disorders, including Sickle Cell and Thalassaemia, living in Barnet, Camden, Enfield, Haringey and Islington.
-
The North Central London Integrated Care System (NCL ICS) has new services and staff training to support patients with inherited red cell disorders, including Sickle Cell and Thalassaemia, living in Barnet, Camden, Enfield, Haringey and Islington.
-
Participants reacted quicker and made fewer errors during menstruation, despite believing their performance would be worse, according to new research from UCL and the Institute of Sport, Exercise & Health (ISEH).
File results
-
FOI/2024/0513 - Robotic platforms for surgery costs/ contract
-
FOI/2024/0514 - Viscosupplementation injections/ spend
-
FOI/2024/0518 - Post partum balloons buying/ usage numbers
-
FOI/2024/0520 - Treatment of melanoma
-
FOI/2024/05523 - Dabrafenib + Trametinib cancer treatment for metastatic and adjuvant melanoma/ lung/ colorectal cancer
-
FOI/2024/0527 - Treatment for renal cell carcinoma
-
FOI/2024/0532 - Patient treatment/ care/ consent
-
FOI/2024/0356 - Treatment with Durvalumab and Nivolumab for biliary tract/ non-small cell lung cancer
-
FOI/2024/0543 - Guidelines, policies for the treatment of obesity/ pathways for Tier 3 or Tier 4 weight management services
-
FOI/2024/0395 - Treatment and services for duchenne muscular dystrophy